Protagenic Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1998
Net Income	-5	-3.56	-4.52	-2.55	-1.75	-2.56	-2.26	-2.28	-1.02	-1.08	Upgrade
Depreciation & Amortization	0.03	0	0	0	0	0	0	0	0	0	Upgrade
Share-Based Compensation	0.67	0.86	1.52	1.65	0.8	1.13	0.89	0.55	0.48	0.28	Upgrade
Other Operating Activities	0.6	0.7	0.21	-0.46	0.46	0.36	-0.01	0.59	0.16	0.01	Upgrade
Operating Cash Flow	-3.7	-1.99	-2.8	-1.35	-0.49	-1.07	-1.38	-1.14	-0.38	-0.79	Upgrade
Capital Expenditures	-0.15	-0	0	0	0	0	0	0	-0	-0	Upgrade
Change in Investments	4.93	1.6	-9.91	0	0.25	1.05	-1.29	0	0	0	Upgrade
Investing Cash Flow	4.78	1.6	-9.91	0	0.25	1.05	-1.29	0	-0	-0	Upgrade
Share Issuance / Repurchase	0	0	12.25	0	0	0	0	0.01	0	0	Upgrade
Debt Issued / Paid	0	0	0	1.22	0.67	0	0	0.02	0.39	0.18	Upgrade
Other Financing Activities	-	-	0.33	-	-	-	-	4.26	-	-	Upgrade
Financing Cash Flow	0	0	12.58	1.22	0.67	0	0	4.28	0.39	0.18	Upgrade
Exchange Rate Effect	0	0.07	0	-0	0	-0.01	-0.03	-0.05	-0.02	0	Upgrade
Net Cash Flow	1.07	-0.33	-0.13	-0.13	0.44	-0.04	-2.7	3.1	-0.02	-0.62	Upgrade
Free Cash Flow	-3.85	-2	-2.8	-1.35	-0.49	-1.07	-1.38	-1.14	-0.38	-0.79	Upgrade
Free Cash Flow Per Share	-0.89	-0.46	-0.76	-0.52	-0.19	-0.42	-0.54	-0.86	-0.23	-122.32	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).